Morning Glory Sciences– Author –
-
Can Bispecific Antibodies Break the ‘Keytruda Ceiling’? — Three Directions Revealed by PD-1xVEGF
This is the fourth installment of our ASCO 2026 in Review series. Of the "five turning points" mapped out in the Prologue (Vol. 1), this piece focuses on a single design philosophy: the bispecific antibody. One of the most closely watche... -
Antibody-Drug Conjugates Break the Tumor-Type Barrier — Reading the 2026 Drug-Development Map Through the Race for Targets
This is the third installment of our ASCO 2026 in Review series. Of the "five turning points" laid out in the Prologue (Vol.1), this issue drills into the turning point of antibody-drug conjugates (ADCs). What echoed repeatedly through t... -
How Far Has ‘Undruggable’ KRAS Fallen? — Pan-RAS Targeting Arrives in Pancreatic Cancer, and the Five Arrows to Come
This is the second installment of our ASCO 2026 in Review series. Of the "five turning points" introduced in the Prologue (Vol.1), this piece confronts the most symbolic—and the one declared "impossible" for longest—of them all: targetin... -
ASCO 2026 in Review — Prologue: The Year Oncology Learned to Translate — A Map of the Modality Revolution and Five Turning Points
This is the first installment — the Prologue — of our six-part "ASCO 2026 in Review" series, a panoramic look at the 2026 ASCO Annual Meeting (American Society of Clinical Oncology). Held over five days at Chicago's McCormick Place from ... -
The Current State of Quantum Computing × Drug Discovery: 3 Practical Inflection Points from the Cleveland Clinic × IBM Trp-cage Milestone | 2026
Cleveland Clinic x IBM Trp-cage quantum simulation, Qubit Pharmaceuticals x Pasqal, IBM Nighthawk roadmap, verified quantum advantage, and the 2026 quantum-drug-discovery state of the art. -
FDA Oncology Approval Archive April–May 2026: Indication & Modality Index | Approval News Hub
Morning Glory Sciences' comprehensive hub for FDA oncology approvals in April–May 2026 (10 key approvals + related), organized by indication and by modality. -
AI Drug Discovery’s Two Layers Complete Map: Operational Transformation Across 5 Vols | AI Drug Discovery Series Hub
Complete hub for the AI Drug Discovery: Two Layers series (5 parts). 5-company map, compound management × AI × robotics, mechanistic modeling, virtual trials, and AI pharmacovigilance across the value chain. -
KRAS Drug Discovery Complete Map: 3 Years That Reshaped the Once-Undruggable Target | KRAS Frontier Series Hub
Complete hub for the KRAS Frontier series (3 parts). The 3-year arc, G12C/G12D/pan-RAS/degrader landscape, 7 Big Pharma × 7 biotech competitive map, 5 reshuffling scenarios through 2027–2030. -
Oncology Drug Approval News Flash: FDA Approves Durvalumab (Imfinzi, AstraZeneca) + BCG for BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
On May 28, 2026, the FDA approved durvalumab (Imfinzi, AstraZeneca) plus BCG (Bacillus Calmette-Guerin) intravesical therapy for adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). In the POTOMAC trial (n=1,018): DFS HR 0.68 (95% CI 0.50-0.93, p=0.0154). This is the first immunotherapy combination regimen approved for NMIBC. -
Oncology Drug Approval News Flash: FDA Approves Pivekimab Sunirine-pvzy (Decnupaz, AbbVie) for Blastic Plasmacytoid Dendritic Cell Neoplasm
On May 27, 2026, the FDA approved pivekimab sunirine-pvzy (Decnupaz), AbbVie's CD123-directed ADC, for adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare hematologic malignancy. In the CADENZA trial: CR + CRc 69.7% in treatment-naive BPDCN (n=33), 15.7% in R/R BPDCN (n=51). This is the first new BPDCN approval in 8 years since tagraxofusp-erzs. -
Oncology Drug Approval News Flash: FDA Approves Datopotamab Deruxtecan-dlnk (Datroway, Daiichi Sankyo/AstraZeneca) for 1L Unresectable or Metastatic TNBC (PD-(L)1 Ineligible)
On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk (Datroway), a TROP2-directed ADC from Daiichi Sankyo/AstraZeneca, for first-line adults with unresectable or metastatic triple-negative breast cancer ineligible for PD-1/PD-L1 inhibitor therapy. In TROPION-Breast02: median PFS 10.8 vs 5.6 mo (HR 0.57, p -
Where Will KRAS Drug Discovery Be Beyond 2027? Player Map and 5 Reshuffling Scenarios | KRAS Frontier Vol.3 (Final)
Competitive map of Revolution, Amgen, BMS, Roche, Lilly, BioNTech, Moderna; SHP2/SOS1 inhibitors, mRNA vaccines, diagnostic linkage, 2027-2030 outlook. -
Redrawing the KRAS Map: G12D, Pan-KRAS, and Degraders Open 4 New Frontiers | KRAS Frontier Vol.2
Revolution Medicines daraxonrasib (pan-RAS) achieved Phase 3 PDAC OS 13.2 vs 6.7 months; zoldonrasib (G12D) earned FDA Breakthrough in NSCLC. -
Where Are KRAS G12C Inhibitors Heading? Sotorasib, Adagrasib, and the 5 Axes of Resistance in 2026 | KRAS Frontier Vol.1
Sotorasib / adagrasib 2026 clinical status, resistance mechanisms (switch II mutations, EGFR reactivation), KRYSTAL-7 ICI combinations, CRC anti-EGFR approvals. -
Where Is the Response to Early-Onset Cancer Heading? 3 Layers of Implementation — USPSTF Age 45, AI Prediction, Individualized Prevention | Vol.3 (Final)
USPSTF age-45 implementation, GRAIL Galleri, AI x multi-omics, individualized prevention, and the expansion of dedicated young-onset cancer clinics. -
What the Exposome Reveals About Early-Onset Cancer: 4 Axes (Diet, Microbiome, Microplastics, Metabolism) and the Unified Life-Course Model | Vol.2
Unified life-course model integrating UPF, gut microbiome, microplastics, PFAS, and metabolic dysregulation. Includes F. nucleatum stem-cell reprogramming and the latest 2026 reviews. -
The Cohort Effect Behind Rising Young-Adult Cancer: A Lineage of Epidemiology Across 10+ Cancer Types Since the 1960s | Vol.1
ACS 2026 statistics: colorectal cancer is now the #1 cancer death cause for U.S. adults under 50. Ten+ cancer types are rising in younger cohorts; 1960s-onward birth cohorts show systematic risk. -
The Future of Pharmacovigilance: AI and Machine Learning Reshaping Adverse-Event Detection Across 3 Axes | Vol.5 (Final)
AI in pharmacovigilance — FDA/PMDA initiatives, social media and EHR-based signal detection, the future of drug safety. -
What ChatGPT Health Misses in Medical Triage: The U-Shaped Failure Structure and 48% Emergency Undertriage Across 960 Responses | Nature Medicine, May 2026
Nature Medicine, May 2026: a structured 960-response test of ChatGPT Health's triage. 48% of emergencies undertriaged. Anchoring bias OR 11.7. Crisis safeguards activate counterintuitively. -
Oncology Drug Approval News Flash: FDA Approves Atezolizumab (Tecentriq, Genentech/Roche) for Adjuvant Treatment of Muscle-Invasive Bladder Cancer in Patients with Molecular Residual Disease
On May 15, 2026, the FDA approved atezolizumab (Tecentriq, Genentech/Roche) for adjuvant treatment of muscle-invasive bladder cancer in patients with molecular residual disease (MRD), marking a landmark biomarker-guided approval in urothelial carcinoma.
